Loading stock data…
$1.73+0.05 (+2.68%)
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Black Diamond Therapeutics, Inc. in the Healthcare sector is trading at $1.73 with a market capitalization of $116M. Wall Street consensus targets $10.00 (7 analysts), implying a +479.7% move over the next 12 months. The stock is currently near its 52-week low of $1.60, remaining 23.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.06M↓ | -$11.26M↓ | -$10.26M↑ | -$10.98M↑ | -$13.42M |
| Net Income | -$9.90M↓ | -$9.04M↑ | -$15.12M↓ | -$8.50M↑ | -$10.56M |
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant...